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Yet again, the humble soybean has undergone a further cycle of
critical scrutiny. The extent to which soy foods and products—or,
more relevantly, one of the constituent bioactive components,
genistein—pose potential health benefits or risks has once again
come under the microscope. Hot on the heels of the American
Heart Association’s conclusions that soy has little effect on reducing
cholesterol or improving other cardiovascular risk markers (Sacks et
al. 2006), there has been yet a further review of the safety of genis-
tein and soy infant formula, this time by a panel of 14 independent
“experts” convened by the National Toxicology Program’s Center
for the Evaluation of Risks to Human Reproduction (NTP-
CERHR 2006a, 2006b). Two separate draft reports comprehen-
sively document an extensive literature published on the
reproductive and developmental toxicity of genistein, and on soy
infant formula, respectively. Following a public forum held in
Washington, DC, in March 2006, these reports concluded that
there is negligible concern for genistein in the general adult popula-
tion, although there are insufficient data to permit conclusions for
soy formula. Given 40 years’ use of soy formula in an estimated
25–30 million infants, this paucity of information in the scientific
literature could and should be taken as compelling evidence of the
assurance of the safety of soy infant formula. Certainly if soy infant
formula were a “drug entity,” with this track record its safety would
never be in question. So why, then, has there been so much contro-
versy over soy’s safety? After all, the soybean is a vegetable protein
of the highest quality, has no cholesterol, is high in unsaturated
fats, is a good source of fiber and complex carbohydrates, and is free
of lactose. It is a food consumed daily by millions of adults and
children in Asia, where the incidence of hormone-dependent dis-
eases is relatively low (although now increasing) compared with
countries where soy is not typically consumed. Central to this issue
is the fact that the soybean is the champion plant species in delivering
a dietary source of isoflavones, an important class of phytoestrogen.
Genistein is clearly a bioactive molecule. It displays characteris-
tics of a selective estrogen receptor (ER) modulator (SERM) rather
than an estrogen (Pike et al. 1999), showing affinity for ERβ
(Kuiper et al. 1998), and this distinction has implications for its
potential actions. It has many nonhormonal activities relevant to
potential effects at the cellular and molecular level. However, genis-
tein, with few exceptions, is not a major isoflavone of most soy
foods and products consumed in Western countries, unless these
have undergone fermentation, as in traditional foods such as tem-
peh, natto, and to some extent miso, consumed mainly by Asians
(Coward et al. 1993). It accounts for < 2% of the isoflavone con-
tent of the soybean, soy proteins, and most Western soy foods,
including soy infant formulas. Although innumerable studies in
animal models, mostly rodents, clearly show that purified genis-
tein can induce adverse reproductive effects, most of these find-
ings have little relevance to humans consuming soy foods, and
especially to infants fed soy formulas.
In elucidating the safety and toxicity of isoflavones in soy
foods, one might ask why genistin and daidzin have not been
tested. After all, these are the major isoflavones of soybeans and
most soy foods, and these
compounds are commer-
cially available. The answer
is simple: These sugar con-
jugates would be largely
devoid of in vitro activity,
and in vivo would have
no overt reproductive toxi-
city, even though biologic
responses would be expected
at the cellular and molecular
level. Soy meal is a key
ingredient of most commer-
cial rodent diets routinely
used by animal breeding
establishments and research
institutes, and rats and mice
are exposed to doses ranging
80–160 mg/kg bw of total isoflavones, higher than doses of puri-
fied genistein injected in many toxicologic rodent experiments
revealing adverse events (Brown and Setchell 2001; Thigpen et al.
2004). Furthermore, soy meal is routinely fed to domestic farm
animals as an important source of protein, with no apparent repro-
ductive toxicity. As a point of reference, exposure via soy foods is
0.5–1.5 mg/kg body weight for total isoflavones in adults, of which
genistein accounts for only 0.005–0.015 mg/kg body weight,
whereas exposures are an order of magnitude higher in infants fed
soy formulas (Setchell et al. 1997, 1998).
Route of administration, animal model, species differences,
and metabolism are the most crucial factors in considering the
effects of genistein. The mouse, rat, and monkey metabolize soy
isoflavones differently from human adults and infants, producing
almost exclusively equol (Setchell et al. 2002, 2005). Little genis-
tein circulates after feeding soy to rodents, so why is genistein
used to predict isoflavone exposure from soy in this species?
Indeed, emerging microarray and molecular studies comparing
genistein with soy show just how differently these two entities
behave (Ronas et al. 2006); and this holds true for genistein and
estradiol (Diel et al. 2000). Genistein behaves differently when
injected versus given orally, and herein lies the problem in making
extrapolations. The intestine provides a key barrier to limiting the
bioavailability and biologic activity of isoflavones administered
orally. Delivery of genistein by injection bypasses first-pass metab-
olism and leads to plasma concentrations of free genistein that are
far higher than if administered orally, particularly at high doses.
Finding isoflavone concentrations in rodents given genistein to be
comparable to those of infants fed soy formula is of little relevance
when route of administration differs. If a drug is to be given
orally, the Food and Drug Administration requires assessment of
safety/toxicity by the oral route, and this should be the rule
for isoflavones when designing studies evaluating the risks of
soy foods. Finally, although the prenatal/neonatal rodent has
proven an appropriate model for in utero human exposure to an
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endocrine disruptor, as illustrated in excellent studies of diethyl-
stilbestrol (McLachlan et al. 1980, 2001; Newbold 2004; Yoshida
et al. 1999), it is of little value for assessing postnatal development
of infants exposed to isoflavones from soy formula. The only
appropriate model for postnatal human reproductive development
is the human infant.
Confidence in the data from clinical studies has been shaken by
the high variability in the findings from clinical studies of soy pro-
tein and soy foods. Although not at all surprising, given the lack of
consistency among study designs, this has diminished consumer
confidence for soy as a healthy food option. A legitimate area of
concern is soy use in Western women diagnosed with breast cancer
and in those at high risk for breast cancer. Recommendations for
the former are difficult to make at this time, but encouraging find-
ings for the prophylactic effect of the SERM raloxifene on breast
cancer may offer some promise for soy in the latter group
(Cummings et al. 1999; Martino et al. 2004, 2005). To expect that
soy and its constituent isoflavones will reverse or arrest chronic dis-
ease is asking too much of this small bean. The greatest potential
for soy lies not in using it to treat pathologic changes that are usu-
ally irreversible, but in including it in the diet early in life, which
will, by whatever mechanism, offer the potential for preventing
chronic diseases. What is needed is a move toward prospective
studies to demonstrate the risk/benefit of soy and its bioactive con-
stituents, whether isoflavones, protein, or other components, rather
than more animal studies that will unquestionably show many of
the same effects already well documented. Might there be long-
term health benefits from early feeding of soy formula or soy foods
to children? Until such studies are executed and data available,
there will be no resolution on this issue, and we face the prospect
of throwing the baby out with the bathwater. Common sense
should prevail.
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If a drug is to be given orally, the Food and Drug Administration requires assessment
of safety/toxicity by the oral route, and this should be the rule for isoflavones when
designing studies evaluating the risks of soy foods.